Antimicrobial Agents for Complicated Skin and Skin‐Structure Infections: Justification of Noninferiority Margins in the Absence of Placebo‐Controlled Trials
Open Access
- 1 August 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (3) , 383-391
- https://doi.org/10.1086/600296
Abstract
Background. The United States Food and Drug Administration requires clinical trial noninferiority margins to preserve a fraction (eg, 50%) of the estKeywords
This publication has 54 references indexed in Scilit:
- Randomized, Double-Blind, Placebo-Controlled Trial of Cephalexin for Treatment of Uncomplicated Skin Abscesses in a Population at Risk for Community-Acquired Methicillin-Resistant Staphylococcus aureus InfectionAntimicrobial Agents and Chemotherapy, 2007
- Incidence of Lower-Extremity Cellulitis: A Population-Based Study in Olmsted County, MinnesotaMayo Clinic Proceedings, 2007
- The case of the misleading funnel plotBMJ, 2006
- Methicillin-ResistantS. aureusInfections among Patients in the Emergency DepartmentNew England Journal of Medicine, 2006
- Antimicrobial Management of Complicated Skin and Skin Structure Infections in the Era of Emerging ResistanceSurgical Infections, 2005
- Community-Associated MRSA — Resistance and Virulence ConvergeNew England Journal of Medicine, 2005
- Comparative Merits of Sodium and Procaine PenicillinBMJ, 1949
- Case of Erysipeloid of Rosenbach Treated with PenicillinBMJ, 1949
- PENICILLIN THERAPY IN SCARLET FEVERThe Lancet, 1948
- Topical use of streptomycin in woundsThe American Journal of Medicine, 1947